Identification of serum biomarkers for canine B-cell lymphoma by use of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry

Patrick J. Gaines Heska Corp, 3760 Rocky Mountain Ave, Loveland, CO 80538

Search for other papers by Patrick J. Gaines in
Current site
Google Scholar
PubMed
Close
 MS
,
Timothy D. Powell Heska Corp, 3760 Rocky Mountain Ave, Loveland, CO 80538

Search for other papers by Timothy D. Powell in
Current site
Google Scholar
PubMed
Close
 BS
,
Scott J. Walmsley Heska Corp, 3760 Rocky Mountain Ave, Loveland, CO 80538

Search for other papers by Scott J. Walmsley in
Current site
Google Scholar
PubMed
Close
 BS
,
Kevin L. Estredge Heska Corp, 3760 Rocky Mountain Ave, Loveland, CO 80538

Search for other papers by Kevin L. Estredge in
Current site
Google Scholar
PubMed
Close
,
Nancy Wisnewski Heska Corp, 3760 Rocky Mountain Ave, Loveland, CO 80538

Search for other papers by Nancy Wisnewski in
Current site
Google Scholar
PubMed
Close
 PhD
,
Dan T. Stinchcomb Heska Corp, 3760 Rocky Mountain Ave, Loveland, CO 80538

Search for other papers by Dan T. Stinchcomb in
Current site
Google Scholar
PubMed
Close
 PhD
,
Stephen J. Withrow Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523

Search for other papers by Stephen J. Withrow in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Susan E. Lana Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523

Search for other papers by Susan E. Lana in
Current site
Google Scholar
PubMed
Close
 DVM, MS

Abstract

Objective—To identify biomarker proteins for B-cell lymphoma in canine serum by use of surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry and build classification trees with multiple biomarkers that have high sensitivity and specificity for that tumor type.

Sample Population—Sera from 29 dogs with B-cell lymphoma and 87 control dogs (approx equal numbers of healthy dogs, dogs with malignant cancers other than B-cell lymphoma, and dogs with various nonneoplastic diseases or conditions).

Procedures—Serum samples were fractionated chromatographically and analyzed via SELDI-TOF mass spectrometry. Peak amplitudes of the spectra from the 2 sample groups were compared to identify potential biomarker peaks, and classification trees were built by use of computer software to detect patterns formed by multiple biomarkers among SELDI data sets.

Results—Several biomarker protein peaks in canine serum were identified, and a classification tree was built on the basis of 3 biomarker protein peaks. With 10-fold cross-validation of the sample set, the best individual serum biomarker peak had 75% sensitivity and 86% specificity and the classification tree had 97% sensitivity and 91% specificity for the classification of B-cell lymphoma.

Conclusions and Clinical Relevance—On the basis of biomarker proteins identified in canine serum, classification trees were constructed, which may be useful for the development of a diagnostic test for B-cell lymphoma in dogs. Further investigation is needed to determine whether these biomarkers are useful for screening susceptible dog populations or for monitoring disease status during treatment and remission of B-cell lymphoma in dogs.

Abstract

Objective—To identify biomarker proteins for B-cell lymphoma in canine serum by use of surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry and build classification trees with multiple biomarkers that have high sensitivity and specificity for that tumor type.

Sample Population—Sera from 29 dogs with B-cell lymphoma and 87 control dogs (approx equal numbers of healthy dogs, dogs with malignant cancers other than B-cell lymphoma, and dogs with various nonneoplastic diseases or conditions).

Procedures—Serum samples were fractionated chromatographically and analyzed via SELDI-TOF mass spectrometry. Peak amplitudes of the spectra from the 2 sample groups were compared to identify potential biomarker peaks, and classification trees were built by use of computer software to detect patterns formed by multiple biomarkers among SELDI data sets.

Results—Several biomarker protein peaks in canine serum were identified, and a classification tree was built on the basis of 3 biomarker protein peaks. With 10-fold cross-validation of the sample set, the best individual serum biomarker peak had 75% sensitivity and 86% specificity and the classification tree had 97% sensitivity and 91% specificity for the classification of B-cell lymphoma.

Conclusions and Clinical Relevance—On the basis of biomarker proteins identified in canine serum, classification trees were constructed, which may be useful for the development of a diagnostic test for B-cell lymphoma in dogs. Further investigation is needed to determine whether these biomarkers are useful for screening susceptible dog populations or for monitoring disease status during treatment and remission of B-cell lymphoma in dogs.

  • 1

    Vail DM, MacEwen GE, Young KM. Canine lymphoma and lymphoid leukemias. In:Withrow SJ, MacEwen GE, ed.Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;558590.

    • Search Google Scholar
    • Export Citation
  • 2

    Alaiya A, Al-Mohanna M, Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005;4:12131222.

  • 3

    Veenstra TD, Conrads TP, Hood BL, et al. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005;4:409418.

  • 4

    Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683695.

  • 5

    Westermeier R, Marouga R. Protein detection methods in proteomics research. Biosci Rep 2005;25:1932.

  • 6

    Low TY, Seow TK, Chung MC. Separation of human erythrocyte membrane associated proteins with one-dimensional and two-dimensional gel electrophoresis followed by identification with matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics 2002;2:12291239.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Mirgorodskaya E, Braeure C, Fucini P, et al. Nanoflow liquid chromatography coupled to matrix-assisted laser desorption/ ionization mass spectrometry: sample preparation, data analysis, and application to the analysis of complex peptide mixtures. Proteomics 2005;5:399408.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8

    Xiao Z, Prieto D, Conrads TP, et al. Proteomic pattern: their potential for disease diagnosis. Mol Cell Endocrinol 2005;230:95106.

  • 9

    Peticoin EF, Liotta LA. SELDI-TOF based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:2430.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572577.

  • 11

    Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:36093613.

    • Search Google Scholar
    • Export Citation
  • 12

    Forterre S, Ralia J, Schweigert FJ. Protein profiling of urine from dogs with renal disease using ProteinChip analysis. J Vet Diagn Invest 2004;16:271277.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13

    Forterre S, Raila J, Kohn B, et al. Protein profiling of organic stone matrix and urine from dogs with urolithiasis. J Anim Physiol Nutr (Berl) 2006;90:192199.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14

    Hu J, Coombes KR, Morris JS, et al. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005;3:322331.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    Villanueva J, Phillip J, Chaparro CA, et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 2005;4:10601072.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16

    Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov, et al.Ovarian cancer marker of 11.7 kDa detected by proteomics is serum amyloid A1. Proteomics 2005;5:37903797.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17

    Anderson LN, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;11:845867.

    • Search Google Scholar
    • Export Citation
  • 18

    LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 2005;4:10531059.

Advertisement